Companies / Bangladesh
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Roche Offers More ARV Technology Transfer Deals
January 2008 | Company News AlertSorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
Swiss drugmaker Roche has expanded its Technology Transfer Initiative for the production of generic versions of the company's patented second line antiretroviral (ARV) Invirase (saquinavir) to four local manufacturers in Africa and Asia. The deal will allow saquinavir to be produced by Regal Pharmaceuticals in Kenya, CAPS Holdings in Zimbabwe, Shely's Pharmaceuticals in Tanzania and Bexmico Pharmaceuticals in Bangladesh. Already included in the initiative are South Africa's Aspen and Cosmos, and Universal Corporation in